Theratechnologies (THERF) Downgraded by ValuEngine to Hold
ValuEngine downgraded shares of Theratechnologies (OTCMKTS:THERF) from a buy rating to a hold rating in a research report sent to investors on Tuesday morning.
OTCMKTS:THERF opened at $7.33 on Tuesday. The company has a quick ratio of 1.22, a current ratio of 1.56 and a debt-to-equity ratio of 0.11. Theratechnologies has a 1-year low of $3.90 and a 1-year high of $11.25.
Theratechnologies (OTCMKTS:THERF) last announced its quarterly earnings data on Thursday, July 5th. The company reported ($0.02) EPS for the quarter. Theratechnologies had a negative net margin of 26.30% and a negative return on equity of 28.47%. The firm had revenue of $9.60 million for the quarter.
Theratechnologies Inc, a specialty pharmaceutical company, addresses unmet medical needs to promote healthy living and improve quality of life among HIV patients. The company's lead product is EGRIFTA, which increases the incidence or progression of diabetic retinopathy in diabetic HIV-infected patients with lipodystrophy and excess abdominal fat in the United States and Canada.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Theratechnologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theratechnologies and related companies with MarketBeat.com's FREE daily email newsletter.